US2003087384A1PendingUtilityA1
Fibroblast growth factor receptor-like molecules and uses thereof
Assignee: AMGEN INC A CORP OF THE STATEPriority: Mar 22, 2000Filed: Aug 28, 2002Published: May 8, 2003
Est. expiryMar 22, 2020(expired)· nominal 20-yr term from priority
A61P 7/00A61P 3/14A61P 3/10A61P 3/04A61P 9/00A61P 7/06A61P 35/00A61P 43/00A61P 17/02A61K 38/00A01K 2217/05A61K 35/12C07K 2319/00A61P 19/08C12N 2799/021C07K 14/71A61P 19/10A61P 19/00A61P 13/12A61P 1/02A61K 49/0004
46
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated nucleic acid molecule comprising:
(a) the nucleotide sequence as set forth in SEQ ID NO: 4; (b) a nucleotide sequence encoding the polypeptide as set forth in SEQ ID NO: 5; (c) a nucleotide sequence which hybridizes under at least moderately stringent conditions to the complement of the nucleotide sequence of either (a) or (b), wherein the encoded polypeptide has an activity of the polypeptide as set forth in SEQ ID NO: 5; or (d) a nucleotide sequence complementary to the nucleotide sequence of any of (a)-(c).
2 . An isolated nucleic acid molecule comprising:
(a) a nucleotide sequence encoding a polypeptide that is at least about 70 percent identical to the polypeptide as set forth in SEQ ID NO: 5, wherein the encoded polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 5; (b) a nucleotide sequence encoding an allelic variant or splice variant of the nucleotide sequence as set forth in SEQ ID NO: 4, or the nucleotide sequence of (a); (c) a region of the nucleotide sequence of SEQ ID NO: 4, or the nucleotide sequence of either (a) or (b), encoding a polypeptide fragment of at least about 25 amino acid residues, wherein the polypeptide fragment has an activity of the encoded polypeptide as set forth in SEQ ID NO: 5, or is antigenic; (d) a region of the nucleotide sequence of SEQ ID NO: 4, or the nucleotide sequence of any of (a)-(c) comprising a fragment of at least about 16 nucleotides; (e) a nucleotide sequence that hybridizes under at least moderately stringent conditions to the complement of the nucleotide sequence of any of (a)-(d), wherein the encoded polypeptide has an activity of the polypeptide as set forth in SEQ ID NO: 5; or (f) a nucleotide sequence complementary to the nucleotide sequence of any of (a)-(e).
3 . An isolated nucleic acid molecule comprising:
(a) a nucleotide sequence encoding a polypeptide as set forth in SEQ ID NO: 5 with at least one conservative amino acid substitution, wherein the encoded polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 5; (b) a nucleotide sequence encoding a polypeptide as set forth in SEQ ID NO: 5 with at least one amino acid insertion, wherein the encoded polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 5; (c) a nucleotide sequence encoding a polypeptide as set forth in SEQ ID NO: 5 with at least one amino acid deletion, wherein the encoded polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 5; (d) a nucleotide sequence encoding a polypeptide as set forth in SEQ ID NO: 5 which has a C- and/or N-terminal truncation, wherein the encoded polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 5; (e) a nucleotide sequence encoding a polypeptide as set forth in SEQ ID NO: 5 with at least one modification that is an amino acid substitution, amino acid insertion, amino acid deletion, C-terminal truncation, or N-terminal truncation, wherein the encoded polypeptide has an activity of the polypeptide set forth in SEQ ID NO: 5; (f) a nucleotide sequence of any of (a)-(e) comprising a fragment of at least about 16 nucleotides; (g) a nucleotide sequence that hybridizes under at least moderately stringent conditions to the complement of the nucleotide sequence of any of (a)-(f), wherein the encoded polypeptide has an activity of the polypeptide as set forth in SEQ ID NO: 5; or (h) a nucleotide sequence complementary to any of (a)-(g).
4 . A vector comprising the nucleic acid molecule of any of claims 1 , 2 , or 3 .
5 . A host cell comprising the vector of claim 4 .
6 . The host cell of claim 5 that is a eukaryotic cell.
7 . The host cell of claim 5 that is a prokaryotic cell.
8 . A process of producing an FGFR-L polypeptide comprising culturing the host cell of claim 5 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.
9 . The process of claim 8 , wherein the nucleic acid molecule comprises promoter DNA other than the promoter DNA for the native FGFR-L polypeptide operatively linked to the DNA encoding the FGFR-L polypeptide.
10 . The isolated nucleic acid molecule according to claim 2 , wherein the percent identity is determined using a computer program that is GAP, BLASTN, FASTA, BLASTA, BLASTX, BestFit, or the Smith-Waterman algorithm.Join the waitlist — get patent alerts
Track US2003087384A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.